VR Adviser, LLC Q4 2022 Filing
Filed February 14, 2023
Portfolio Value
$622.9T
Holdings
29
Report Date
Q4 2022
Filing Type
13F-HR
All Holdings (29 positions)
| # | Stock | Shares | Value | % Portfolio | Type |
|---|---|---|---|---|---|
| 1 | VRDNVIRIDIAN THERAPEUTICS INC | 2,699,865 | $78.9T | 12.66% | |
| 2 | ACRSACLARIS THERAPEUTICS INC | 4,563,962 | $71.9T | 11.54% | |
| 3 | AXSMAXSOME THERAPEUTICS INC | 670,718 | $51.7T | 8.31% | |
| 4 | COGTCOGENT BIOSCIENCES INC | 4,038,117 | $46.7T | 7.49% | |
| 5 | TERNTERNS PHARMACEUTICALS INC | 3,707,891 | $37.7T | 6.06% | |
| 6 | GHRSGH RESEARCH PLC | 3,517,125 | $34.2T | 5.49% | |
| 7 | CELCCELCUITY INC | 2,105,386 | $29.5T | 4.74% | |
| 8 | —DBV TECHNOLOGIES S A | 9,300,000 | $29.3T | 4.70% | |
| 9 | —DICE THERAPEUTICS INC | 819,000 | $25.6T | 4.10% | |
| 10 | AVTEAEROVATE THERAPEUTICS INC | 747,869 | $21.9T | 3.52% | |
| 11 | PLRXPLIANT THERAPEUTICS INC | 1,080,000 | $20.9T | 3.35% | |
| 12 | KALVKALVISTA PHARMACEUTICALS INC | 2,916,667 | $19.7T | 3.17% | |
| 13 | NVV1NOVAVAX INC | 1,879,894 | $19.3T | 3.10% | |
| 14 | MRUSMERUS N V | 1,226,214 | $19.0T | 3.05% | |
| 15 | CABACABALETTA BIO INC | 1,895,285 | $17.5T | 2.81% | |
| 16 | ANNXANNEXON INC | 3,220,050 | $16.6T | 2.67% | |
| 17 | —VECTIVBIO HLDG AG | 1,866,000 | $16.2T | 2.60% | |
| 18 | PRVBUSDPROVENTION BIO INC | 1,118,653 | $11.8T | 1.90% | |
| 19 | YB4PSAVARA INC | 6,351,531 | $9.8T | 1.58% | |
| 20 | MISTMILESTONE PHARMACEUTICALS IN | 2,208,812 | $8.7T | 1.40% | |
| 21 | LIANYLIANBIO | 4,793,047 | $7.9T | 1.26% | |
| 22 | MRNS*MARINUS PHARMACEUTICALS INC | 1,770,705 | $7.0T | 1.13% | |
| 23 | TRVITREVI THERAPEUTICS INC | 3,050,022 | $5.9T | 0.95% | |
| 24 | FULCFULCRUM THERAPEUTICS INC | 447,326 | $3.3T | 0.52% | |
| 25 | LYRALYRA THERAPEUTICS INC | 924,170 | $2.9T | 0.47% | |
| 26 | INZYINOZYME PHARMA INC | 2,709,987 | $2.8T | 0.46% | |
| 27 | ATYRATYR PHARMA INC | 1,171,436 | $2.6T | 0.41% | |
| 28 | —AFFIMED N V | 1,428,571 | $1.8T | 0.28% | |
| 29 | RLYBRALLYBIO CORP | 268,532 | $1.8T | 0.28% |